Search
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … It is also present in dental or oral hygiene products due to its cariostatic effects.
Calcium carbonate
go.drugbank.com/drugs/DB06724ApprovedInvestigationalIt is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. … Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.
Mixtures: Super Daily No 2, MILPAX®NFProducts: Ki No Sin, D N B ReNorfloxacin
go.drugbank.com/drugs/DB01059ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Products: N-FLOXA 200, N-FLOXA 400Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] … The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeInternational brands: CO OlanzapineTerpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnElixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies. … It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate
Gliclazide
go.drugbank.com/drugs/DB01120ApprovedInvestigational[T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. … Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).
Products: Nu-gliclazide, DIAMICRON UNO 60MGCetirizine
go.drugbank.com/drugs/DB00341ApprovedInvestigationalThe prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. … Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects [A175060].
Mixtures: Allergy and Congestion Relief D Original Prescription Strength, VERACETAM NF CAPSULASCategories: Histamine H1 Antagonists, Non-SedatingBendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawna small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation. … Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSDaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Products: CUBICIN® 350 MG POLVO PARA SOLUCIÓN INYECTABLE O INFUSIÓN, CUBICIN® 500 MG POLVO PARA SOLUCION INYECTABLE O INFUSIONLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.